electroCore (NASDAQ:ECOR) versus OraSure Technologies (NASDAQ:OSUR) Head-To-Head Analysis

electroCore (NASDAQ:ECOR) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares electroCore and OraSure Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$36.97 million	2.36	-$13.97 million	($1.66)	-5.82
OraSure Technologies	$112.41 million	2.39	-$68.73 million	($0.69)	-5.65

electroCore has higher earnings, but lower revenue than OraSure Technologies. electroCore is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

electroCore has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Insider & Institutional Ownership

26.7% of electroCore shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 7.8% of electroCore shares are held by insiders. Comparatively, 4.7% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares electroCore and OraSure Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-39.96%	N/A	-81.35%
OraSure Technologies	-43.70%	-19.09%	-16.26%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for electroCore and OraSure Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1	1	1	0	2.00
OraSure Technologies	1	2	0	0	1.67

electroCore presently has a consensus price target of $18.00, indicating a potential upside of 86.34%. OraSure Technologies has a consensus price target of $3.00, indicating a potential downside of 23.08%. Given electroCore’s stronger consensus rating and higher probable upside, equities research analysts plainly believe electroCore is more favorable than OraSure Technologies.

Summary

electroCore beats OraSure Technologies on 8 of the 14 factors compared between the two stocks.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.